Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

Conference Call Scheduled for September 17 at 10:30 ET, 7:30 PT

EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced its financial results for its fiscal fourth quarter and year ended June 30, 2007 and announced a planned 1-for-7 reverse split of its common stock.

For fiscal year 2007, the Company reported revenue of $17.7 million, a 44% increase over last year's revenue of $12.3 million. The net loss for fiscal 2007 was $14.1 million, or $0.47 per share, compared with a net loss of $27.8 million, or $0.98 per share, in fiscal year 2006. At June 30, 2007, the Company's balance of available cash, cash equivalents and investment securities was $8.9 million.

For the fourth quarter ended June 30, 2007, the Company reported revenue of $4.0 million compared to $4.3 million for the same period in 2006. The net loss for the quarter ended June 30, 2007 was $4.2 million, or $0.13 per share, compared with a net loss of $4.8 million, or $0.16 per share, for the same period in 2006.

For the fiscal year ended June 30, 2007, the Company reported revenue of $17.7 million consisting of $6.9 million of royalty fees earned from the commercial sales of memantine by Merz + Co. GmbH & Co. (Merz) and its marketing partners in the United States and certain European countries, $5.5 million from the sale of NTI's rights and assets related to XERECEPT(R) to Celtic Pharmaceutical Holdings L.P. (Celtic), and $5.3 million from the reimbursement of the direct expenses incurred for services provided to Celtic for administering the Phase III clinical trials for XERECEPT in the United States. The Company's fiscal year 2006 revenues of $12.3 million
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... , June 25, 2010 Industrial biotechnology ... per year through 2020. Germany ,has already established ... industry, making it an ideal site for,companies looking to ... Invest will be on hand at this year,s World ...
... German . , Organic semiconductors are very ... large area and flexible electronic components such as transistors, diodes ... A condition for success in achieving this goal is the ... in other words, to create an electronic circuit. Empa scientists ...
... ... Company) proffered his views of outsourcing product development trends as they pertain to the design ... science association in the world. , ... Irvine, CA, USA (PRWEB) June 23, 2010 -- BIT Group has ...
Cached Biology Technology:Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 2Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 3Nanowires for the electronics and optoelectronics of the future 2Nanowires for the electronics and optoelectronics of the future 3BIT Group Executive Featured in BioTechnology Series 2BIT Group Executive Featured in BioTechnology Series 3
(Date:10/15/2014)... and to an unexpected extent. The outbreak does not ... virus shows a new disease dynamic in regions, where ... the German National Academy of Sciences Leopoldina, acatech – ... Union of the German Academies of Sciences and Humanities ... , In the statement the academies call for the ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... change in recent decades, but species have adapted to this, ... red deer and wild boar. This has been shown ... in land use on the past, present and future distribution ... has been an increase in the area of distribution of ...
... of biomedical informatics in the Institute for Translational Sciences ... was recently honored for using advanced visual analytical methods ... along with an interdisciplinary team that included ITS director ... Ju and Sundar Victor, received a Distinguished Paper Award ...
... When you think you see a face in the clouds or ... be upside down. It turns out the answer to this ... to. Using tests of visual perception and functional magnetic resonance ... Ontario,s world-renowned Centre for Brain & Mind recently measured activity in ...
Cached Biology News:Changes in land use favor the expansion of wild ungulates 2UTMB's Bhavnani wins award for cutting-edge research in translational bioinformatics 2
Hamster serum...
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
Biology Products: